Harrow Health Stock Today
| HROW Stock | USD 23.32 0.31 1.35% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Harrow Health is selling for under 23.32 as of the 18th of March 2025; that is 1.35 percent increase since the beginning of the trading day. The stock's lowest day price was 22.84. Harrow Health has about a 26 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of September 2007 | Category Healthcare | Classification Health Care |
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Harrow Health operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 35.61 M outstanding shares of which 2.73 M shares are currently shorted by private and institutional investors with about 8.15 trading days to cover. More on Harrow Health
Moving together with Harrow Stock
Moving against Harrow Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Harrow Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Division | John MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHarrow Health can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Harrow Health's financial leverage. It provides some insight into what part of Harrow Health's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Harrow Health (HROW) is traded on NASDAQ Exchange in USA. It is located in 102 Woodmont Boulevard, Nashville, TN, United States, 37205 and employs 315 people. Harrow Health is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 819.49 M. Harrow Health conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 35.61 M outstanding shares of which 2.73 M shares are currently shorted by private and institutional investors with about 8.15 trading days to cover.
Harrow Health currently holds about 51.7 M in cash with 3.84 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.91.
Check Harrow Health Probability Of Bankruptcy
Ownership AllocationHarrow Health has a total of 35.61 Million outstanding shares. Over half of Harrow Health's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Harrow Ownership Details
Harrow Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| First Turn Management Llc | 2024-12-31 | 304.9 K | |
| Royce & Associates, Lp | 2024-12-31 | 292.1 K | |
| Renaissance Technologies Corp | 2024-12-31 | 277.7 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 255.2 K | |
| Gilder Gagnon Howe & Co Llc | 2024-12-31 | 205.8 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 204 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 202.2 K | |
| Neuberger Berman Group Llc | 2024-12-31 | 200.5 K | |
| Voloridge Investment Management, Llc | 2024-12-31 | 188.6 K | |
| Opaleye Management Inc | 2024-12-31 | 4 M | |
| Blackrock Inc | 2024-12-31 | 2.5 M |
Harrow Health Historical Income Statement
Harrow Stock Against Markets
Harrow Health Corporate Management
| Robert DDS | Special Advisor | Profile | |
| Jamie Webb | Director Relations | Profile | |
| PharmD Shojaei | Chief Officer | Profile | |
| David Moufarrge | VP Technology | Profile | |
| RPh Mannebach | Head Pharmacovigilance | Profile | |
| Brett Burrell | Vice Compliance | Profile | |
| CFA CMA | CFO Sec | Profile |
Additional Tools for Harrow Stock Analysis
When running Harrow Health's price analysis, check to measure Harrow Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harrow Health is operating at the current time. Most of Harrow Health's value examination focuses on studying past and present price action to predict the probability of Harrow Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harrow Health's price. Additionally, you may evaluate how the addition of Harrow Health to your portfolios can decrease your overall portfolio volatility.